Allogeneic bone marrow transplantation (ALLO BMT): Role of t cell depletion (TCD) and graft versus host disease (GVHD)

Multiple myeloma is incurable with standard chemotherapy and has a median survival of 3 years from the time of diagnosis. In contrast, alloBMT is potentially curative. It offers the advantage of a tumor-free graft and the potential to induce a graft versus myeloma (GVM) response in the host. However, the toxicity of alloBMT can be considerable in myeloma patients because of their older age and associated comorbidities. From June 1991 to April …